CHMP recommends change of indication for Retsevmo in RET fusion positive non-small cell lung cancer.- Eli Lilly
The CHMP adopted an extension to an existing indication as follows: Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.
The full indication for Retsevmo will be as follows: Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor; advanced RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinib.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.